LN-229 Xenograft

Glioblastoma

The LN-229 cell line was established in 1979 from cells taken from a patient with right frontal parieto-occipital glioblastoma [PubMed. 10416987].

Oncogene

p53 + (mutated, CCT (Pro) --> CTT (Leu) mutation at codon 98), PTEN + (wild type), p16 - (deleted), p14ARF - (deleted)

in vivo

Forms tumors in nude mice

Used in allogeneic xenografts

Request Quote

Receive a quote within one business day for a LN-229 xenograft

DOMESTIC QUALITY

 

When you work with Rincon Bio, rest assured that all cancer efficacy studies will be performed in the USA.  

COMPETITIVE PRICES

 

Because we specialize in tumor models, we're able to offer highly competitive prices.

SPEED TO INITIATION
 

Most efficacy studies can be initiated within two business days.

WORKING 

WITH 

RINCON BIO